Bydureon BCise and Trulicity come as a liquid in a single-dose injector pen, and each drug is injected once per week. For more information about how these drugs compare, see this article.

AstraZeneca announced the availability of Bydureon (exenatide extended-release for injectable suspension) Pen in pharmacies across the country.

The U.S. Food and Drug Administration approved the Bydureon Pen to administer a once weekly medicine for Type 2 diabetes patients. The Bydureon Pen is a pre-filled, single-use pen injector that ...

The FDA approval of the Bydureon Pen offers a new treatment option for these patients, said Rich Daly, president, US Diabetes, AstraZeneca. The innovation is the latest in AstraZeneca's efforts to ...

Bydureon BCise is a prescription drug used to treat type 2 diabetes in adults and some children. Learn about the drug’s dosage, form, strength, and more.

AstraZeneca won U.S. approval of its Bydureon pen for once-weekly treatment of Type 2 diabetes. The pen will be the first of its kind to hit the market. The prefilled, single-use pen injector ...

The FDA has approved Bydureon Pen (exenatide extended-release for injectable suspension; Bristol-Myers Squibb and AstraZeneca) as an adjunct to diet and exercise to improve glycemic control in ...

Bydureon is distributed inside a pen-like device that contains the correct dose of Exenatide and has an auto-injector mechanism hidden inside. There is no need to handle or see the needle but there ...

The BYDUREON Pen is a pre-filled, single-use pen injector, eliminating the need for the patient to transfer the medication between a vial and syringe during the self-injection process.

AstraZeneca's exenatide extended release for injectable suspension (Bydureon Pen) 2 mg is intended for once-weekly use as an adjunct to diet and exercise in the treatment of adults with type 2 ...

The real test will come when the Bydureon pen gets here, which should be late this year or early next year. Until then, I’m not putting too much emphasis on early sales numbers." ...

Bydureon, a glucagon-like peptide-1 receptor agonist, gained approval earlier this year as an adjunct to diet and exercise to improve glycemic control in adults with type II diabetes.